Drugs A-Z Is my price fair? Price changes Drug markups Drug shortages Recalls Medicare prices Upcoming generics What people paid Guides Share what you paid
Theme
Class IITerminatedD-0517-2017

Drug recall · March 22, 2017

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg recall

Why: Failed Impurities/Degradation Specifications

Class II: could cause temporary or reversible health problems; serious harm is remote.

The recall

Product

Buprenorphine and Naloxone Sublingual Tablets 8 mg/2 mg, 30 count HDPE bottles, Rx Only, Distributed by TEVA PHARMACEUTICALS USA, INC., North Wales, PA 19454, NDC 0093-5721-56

Lots / codes

Lot 30227056A; Exp. 03/17

Quantity
7,628 HDPE bottles (228,840 tablets)
Company
Teva Pharmaceuticals USA, North Wales, PA
Distribution
Nationwide
Initiated
February 7, 2017 · Voluntary: Firm initiated
Classified
March 10, 2017
Reported
March 22, 2017
Ended
February 16, 2018
How notified
Letter

The drug: prices, other makers, shortages

If you have this product

  1. Check the lot number on your package against the lots above. Only those lots are recalled.
  2. Don't stop a prescription medicine on your own. Call your pharmacy - they can swap it for an unaffected lot or another maker.
  3. Felt unwell? Contact your doctor, and report it to FDA MedWatch (1-800-FDA-1088 or fda.gov/medwatch).
  4. Return or dispose of recalled product as the company or your pharmacy advises.

Questions about this recall

Be kind and stay on topic. No personal health details, links or selling. This is not medical advice.

No comments yet. Questions, tips, what worked for you - start the conversation.

Watch Naloxone

One email when the price moves, a recall or shortage is posted, or the label changes. Plus the monthly biggest-movers report. Unsubscribe in one click.

Help the next person

Know what your pharmacy pays.

Every price you share shows someone else what's fair - and which pharmacies charge the least. It takes 30 seconds and it's anonymous.